Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR + /HER2 - metastatic breast cancer: a prospective, monocentric study.
Raffaella PalumboErica QuaquariniGiuseppe SaltalamacchiaAlberto MaloviniPietro LapidariBarbara TagliaferriLudovica MollicaCristina Maria TeragniChiara BarlettaLaura Deborah LocatiFederico SottotettiPublished in: Drugs in context (2024)
ET and CT represent two possible therapeutic alternatives for patients progressing on CDK4/6i plus ET. The choice is based on clinical parameters, with a potential preference for ET.
Keyphrases
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- magnetic resonance imaging
- cell cycle
- stem cells
- image quality
- contrast enhanced
- cell proliferation
- mesenchymal stem cells
- risk assessment
- dual energy
- magnetic resonance
- climate change
- patient reported